Publications by authors named "Ahmad Noei"
Chimeric antigen receptor T-cell therapy is a groundbreaking approach for treating certain hematologic malignancies and solid tumors. However, its application is limited by severe toxicities, particularly CRS and ICANS, dramatically limit its broader application. IL-1 plays a crucial role in both enhancing CAR T-cell efficacy and driving these toxic effects.
View Article and Find Full Text PDFArticle Synopsis
- - The study focuses on developing a targeted therapeutic agent, FITC-SpyC-SpyT-CD22Nb, combining SpyCatcher and SpyTag proteins to recognize the CD22 surface protein found in malignant B cells.
- - Researchers used specific molecular techniques to express, purify, and label the proteins, confirming successful binding to CD22+ Raji cells with flow cytometry while showing no interaction with CD22- K562 cells.
- - The results suggest that the FITC-SpyC-SpyT-CD22Nb molecule could be used for precise targeting in cancer therapies like CAR-T cell therapy and antibody-drug conjugates.
Article Synopsis
- * Allogeneic CAR-T cell therapies (allo-CAR-Ts) are being explored as an alternative to autologous therapies, showing promising results in early clinical trials, yet facing challenges like graft-versus-host disease (GvHD) and immune rejection.
- * The success of allo-CAR-Ts depends on factors such as the origin of the starter cells and gene editing techniques, and research is ongoing to address these challenges and maximize their potential for treating hematological malignancies.
Article Synopsis
- The immune system plays a crucial role in identifying and destroying tumor cells, but factors in the tumor microenvironment (TME) can weaken immune responses, making cancer treatment challenging.
- Cancer immunotherapy aims to enhance the immune system's ability to target tumors, with nanobodies (small antibody fragments from camels) showing promise due to their unique characteristics for improving immunotherapy effectiveness.
- Nanobodies facilitate T-cell and natural killer (NK) cell engagement with tumors and can be engineered to target cancer cells directly or block inhibitory signals, enhancing immune surveillance and reducing side effects in cancer treatment.
Backgrounds: Peptide-based drugs have shown promising results in overcoming the limitations of chemotherapeutic drugs by providing a targeted therapy approach to cancer. However, the response rate of targeted therapies is limited, in large part due to the intra- and inter-heterogeneity of tumors.
Methods: In this study, we engineered a novel chimeric protein composed of the p28 peptide as a tumor-homing killer peptide and apoptin as a killer peptide.